Thoraia Shinawi

Dr. Thoraia Shinawi

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2021 in Genes
Verified
Journal Article
Open access
PDF file
HAHeba Alkhatabi
Heba Alkhatabi
HSHaneen Bin saddeq
Haneen Bin saddeq
LALUAY ALYAMANI
LUAY ALYAMANI
TSThoraia Shinawi
Thoraia Shinawi
ELRASHED B. YASINELRASHED B. YASIN
ELRASHED B. YASIN
AAAdel Abuzenadah
Adel Abuzenadah
Different forms of human cancer show mutations for isocitrate dehydrogenases 1 and 2 (IDH1/2). Mutation of these genes can cause aberrant methylation of the genome CpG islands (CGIs), which leads to an increase of suppressed oncogenes transcription or repression of active tumor suppressor gene transcription. This study aimed to identify the prevalence of IDH1/2 mutations in acute leukemia patients. The study cohort included 43 AML patients and 30 childhood ALL patients, from whom DNA bone marrow samples were taken. The alteration hotspots in codons IDH1 (R132) and IDH2 (R172 and R140) were examined via direct sequencing. Mutations in IDH1 were detected in 7 out of 43 (16.2%) AML patients; 5 of them occurred at codon R132. The other two mutations included a single-nucleotide polymorphism, which affected codon G105 in one patient. However, no mutation was detected in the IDH2 in any of the patients. Moreover, no mutations were detected in either IDH1 or IDH2 in ALL patients. The dominance of IDH1 mutations in AML, which was 16%, emphasizes the existence of the mutation in our population. On the other hand, IDH2 mutation was observed to be less frequent in both illnesses. Due to the limitation of using a small sample size, larger cohort screening is recommended to determine their usefulness as prognostic indicators.

30 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
SASultan A. Alfawaz
Sultan A. Alfawaz
HAHaifa Almukadi
Haifa Almukadi
TSThoraia Shinawi
Thoraia Shinawi
DADalal Alfawaz
Dalal Alfawaz
DADareen Alyousfi
Dareen Alyousfi
BBBabajan Banaganapalli
Babajan Banaganapalli
Background/Objectives: Combining omics layers is widely expected to improve cancer drug response prediction, but this is rarely tested under family-wise error control or on an independent screen. We measured what somatic mutation and copy number data add to gene expression, and how well models transfer to unseen lineages and an external screen. Methods: We linked the Cancer Dependency Map transcriptomic, somatic mutation and copy number profiles to GDSC2 dose–response data for twelve mechanistically diverse anticancer compounds in 509 cell lines. Lineage-only, single-modality, early-fusion and stacked late-fusion gradient-boosting models were compared by repeated cross-validation (DeLong tests, Holm adjustment), leave-one-lineage-out transfer across eleven solid tumour histologies, and external validation on 77-163 held-out PRISM cell lines per compound. Results: Gene expression models outperformed tissue-of-origin baselines for all twelve agents (AUC 0.69–0.84; gains 0.024–0.169; Holm-adjusted p < 0.001 for seven drugs). Adding mutation and copy number data changed AUC by −0.015 to +0.035, and no per-drug gain survived multiplicity correction. Pooled across compounds, early fusion added 0.008 AUC (95% CI 0.000–0.016), a gain that fold-level re-analysis did not support. Mixed-lineage cross-validation exceeded leave-one-lineage-out AUC by a median of 0.030 (p = 0.0005). External PRISM AUCs ranged from 0.46 to 0.76 and followed the concordance between the two screens (Spearman rho = 0.72, p = 0.008). TreeSHAP attributions recovered known determinants, including SLFN11, TP53, BRAF, PIK3CA and downstream MAPK transcriptional effectors. Conclusions: In this twelve-drug panel, gene expression captured most of the predictable response variation. Accuracy fell on held-out lineages and on an independent screen, which sets empirical limits on how far these models can generalise.